You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
西藏藥業(600211.SH)2020年度淨利潤升33.87%至4.18億元 擬10派5.1元
格隆匯 03-11 19:29

格隆匯 3 月 11日丨西藏藥業(600211.SH)發佈2020年年度報吿,實現營業收入13.73億元,同比增長9.32%;歸屬於母公司股東淨利潤4.18億元,同比增長33.87%;歸屬於上市公司股東的扣除非經常性損益的淨利潤3.65億元,同比增長19.87%;基本每股收益1.69元,擬按每10股派發現金5.10元(含税)。

公司所處行業為醫藥製造業,主要生產、銷售膠囊劑、生物製劑、顆粒劑、塗膜劑等;公司主要產品涉及心腦血管、肝膽、扭挫傷及風濕、類風濕、感冒等領域,公司產品新活素、依姆多、諾迪康膠囊在心血管疾病的治療中有較強的優勢,因同屬心血管領域,有利於各自市場、學術資源的共享,進一步促進各自的發展。

報吿期內,公司業績穩步增長,全年主營業務收入136,161.30萬元,心血管領域產品新活素、依姆多、諾迪康膠囊佔比94.55%,其中新活素銷售佔全年銷售收入的70.42%,較去年同期增長17.70%依姆多佔全年銷售收入的20.45%,較去年同期增長2.53%;諾迪康佔全年銷售收入的3.68%,較去年同下降3.95%

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account